The effect of a thromboxane receptor antagonist on acute ePTFE arterial graft thrombogenicity--an experimental study in sheep.
ePTFE interposition grafts in the common carotid arteries of 16 adult sheep were used to study the effect of a thromboxane receptor antagonist. Vapiprost (GR 32191, Glaxo research group, London, UK). After insertion of the grafts the sheep were randomised to treatment (n = 8) or control (n = 8). Treatment was given as an intravenous injection with GR 32191 of 1 mg/kg body weight. The flow in one of the two inserted grafts was restricted from normal (190 ml/min) to 25 ml/min. Autologous 111-In labelled platelets and human 125-I labelled fibrinogen were injected intravenously. The radioactivity over each graft was measured for 4 h at two separate points with a gamma scintillation technique. Due to technical complications immediately before the start of the measurements one sheep in each group was excluded from the study. In the treated group three out of seven grafts with restricted flow occluded compared to all seven grafts with a flow reduction in the control group (p less than 0.05). The grafts with unrestricted flow occluded in two of seven in both groups. In the open grafts with unrestricted flow the fibrinogen activity was significantly reduced in the treated group compared to the control group. The platelet activity was not significantly reduced. It is concluded that GR 32191 significantly reduced the fibrinogen uptake as well as graft occlusions of ePTFE grafts in a low flow situation.
Lundell
A
A
University of Lund, Department of Surgery, Sweden.
Bergqvist
D
D
Leide
S
S
Lindblad
B
B
Ljungberg
J
J
D000208:Acute Disease; D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D002339:Carotid Arteries / Q000601:surgery*; D004195:Disease Models, Animal; D005260:Female; D006083:Graft Occlusion, Vascular / Q000139:chemically induced / Q000517:prevention & control*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D008297:Male; D011138:Polytetrafluoroethylene / Q000009:adverse effects*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D017482:Receptors, Thromboxane; D012756:Sheep; D013927:Thrombosis / Q000139:chemically induced / Q000517:prevention & control*
D001713:Biphenyl Compounds; D006538:Heptanoic Acids; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D011138:Polytetrafluoroethylene; C060013:vapiprost